In this study, we aimed to elucidate these issues via the following clinical evaluations: (a) determining the correlations of plasma levels of sPD-L1 with the severity of CAD, (b) exploring the association of plasma sPD-L1 with blood-based inflammation markers such as hs-CRP and a panel of other cytokines, and (c) evaluating the predictive value of sPD-L1 for ACS. The gene discussed is SPDL1; the disease is coronary artery disorder.